



7th HAEMOPHILIA ACADEMY

13-14 March 2018



Program

SCIENTIFIC PROGRAMME

13 MARCH 2018

9.00–9.15

Introduction

László Nemes, Hungary

9.15–10.45

Roundtable Experts Panel: The inhibitors

Moderator: László Nemes, Hungary

Experts and topics:

- Patient-related risks for inhibitor development
– What do the genes tell us?
Anna Pavlova, Germany
- The impact of replacement factors on inhibitor risk
– What have we known till now?
Jerzy Windyga, Poland

10.45–11.25

New trends in haemophilia treatment

Csongor Kiss, Hungary

11.25–11.40

Coffee break

11.40–12.20

Management of life threatening bleedings in patients with haemophilia

Peter Salaj, Czech Republic

12.20–13.20

Lunch

13.20–14.00

Management of acquired haemophilia in 2018

Jerzy Windyga, Poland

14.00–14.20

Coffee break

14.20–16.35 **PARALLEL WORKSHOP SESSIONS**

SESSION I – JOINT HEALTH

CHAIRMAN: **MÁRIA KARDOS, HUNGARY**

- 14.20–14.50 Prosthesis replacement in hemophiliacs according to our department's practice
Lajos Bartha, Hungary
- 14.50–15.20 Orthopaedic surgery in adult haemophilia patients: What is role of a haematologist?
Predrag Miljić, Serbia
- 15.20–15.50 The role of radiosynoviorthesis and viscosupplementation in the treatment of joint bleedings of haemophiliacs
Imre Szerb, Hungary
- 15.50–16.20 Cooperation between haematologists and physiotherapists
Mária Kardos, Hungary

SESSION II – RARE BLEEDING DISORDERS AND ACQUIRED HAEMOPHILIA

CHAIRMAN: **LÁSZLÓ NEMES, HUNGARY**

- 14.20–14.50 Management of rare bleeding disorders in 2018: Congenital deficiency of clotting factor VII and Glanzmann thrombasthenia
Magdalena Górska-Kosicka, Poland
- 14.50–15.20 Congenital factor VII deficiency: What we learned from analyses of Seven Treatment Evaluation Registry (STER)?
Angelika Batorova, Slovakia
- 15.20–15.50 Management of invasive procedures in FVII deficiency
László Nemes, Hungary
- 15.50–16.05 Severe inherited FVII deficiency – an attempt of prophylaxis
Dragan Mičić, Serbia
- 16.05–16.20 Pregnancy associated acquired haemophilia, a case report
Tatjana Smilevska, Svetlana Stankovikj, Macedonia
- 16.20–16.35 Acquired hemophilia – real life diagnostic and treatment
Nebojša Rajić, Serbia

14 MARCH 2018

8.00–8.40 **Orthopaedic management
of haemophilia arthropathy of the ankle**
Piero Luigi Solimeno, Italy

8.40–10.10 **Roundtable Experts Panel:
Individualising approaches
for patients with haemophilia**
Moderator: Csongor Kiss, Hungary

Experts and topics:

- “Intelligent” rFVIIIs with opportunity
for individualising patient management?
Csongor Kiss, Hungary
- Factor VIII pharmacokinetic dose tailoring
– suggestions for clinical practice
Massimo Morfini, Italy
- Optimization of bleeding management with
rFVIIa in patients with haemophilia and inhibitors
Silva Zupančić Šalek, Croatia

10.10–10.25 *Coffee break*

10.25–11.40	Clinical Cases Workshop Atanas Banchev, Bulgaria
10.25–10.40	Long half-life of a standard rFVIII product in a patient with severe haemophilia A, requiring double anti-aggregation therapy and dialysis treatment, a case report Sasa Anzej Doma, Irena Preloznik Zupan, Slovenia
10.40–10.55	Individualised prophylaxis with rFVIII in two children with severe haemophilia A Zorica Trajkova-Antevska, Macedonia
10.55–11.10	Comparing haemophilia joint health Germany vs. Bulgaria – What shall we do better? Interim analysis comparing joint bleeding rate, clinical and sonographic examination Atanas Banchev, Bulgaria
11.10–11.50	The role of the physiotherapy in haemophilia cares Sebastien Lobet, Belgium
11.50–12.30	Efficacy and safety of extended half-life recombinant clotting factor IX (N9GP, nonacog beta pegol) Brit Binow Sørensen, <i>Director Medical Affairs Biopharm,</i> <i>Novo Nordisk Region Europe</i>
12.30–12.40	Closing remarks László Nemes, Hungary
12.40–14.00	<i>Lunch</i>
14.00–	<i>Departures</i>